Construction of a New Tablet Manufacturing Building, the Sixth Formulation Building, at the Toyama Plant
First written in FY2020. 6 of 9 entries say "Restated". Latest entry: FY2023-Q3.
0 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「To meet growing demand for these core products, the new tablet building constructed at the Toyama Plant to manufacture hormone tablets is scheduled to begin full-scale operations in 2023. We will expand hormone-tablet production capacity, contribute further to improving women's well-being and fulfil our responsibility to ensure a stable supply.」
Continues to state that the new tablet manufacturing building at the Toyama Plant will begin full-scale operations in 2023 and that the company plans to expand hormone tablet production capacity. - FY2023-Q2RestatedAnnual report
「To meet growing demand for these core products, the new tablet building constructed at the Toyama Plant to manufacture hormone tablets is scheduled to begin full-scale operations in 2023. We will expand hormone-tablet production capacity, contribute further to improving women's well-being and fulfil our responsibility to ensure a stable supply.」
Continues to plan for the new tablet manufacturing building constructed at the Toyama Plant to begin full-scale operations in 2023 and expand production capacity. - FY2023-Q1RestatedAnnual report
「To meet growing demand for these core products, the new tablet building constructed at the Toyama Plant to manufacture hormone tablets is scheduled to begin full-scale operations in 2023. We will expand hormone-tablet production capacity, contribute further to improving women's well-being and fulfil our responsibility to ensure a stable supply.」
Continues to state that the new tablet manufacturing building at the Toyama Plant is scheduled to begin full-scale operations in 2023 and will contribute to expanded production capacity and a stable supply. - FY2022RestatedAnnual report
「To meet increased demand for these major products, the company is constructing a new tablet manufacturing building at its Toyama Plant and plans to begin full-scale operations in 2023. The company will expand hormone tablet production capacity and fulfill its responsibility to ensure a stable supply.」
The company continues to plan the construction of a new tablet manufacturing building to meet increased demand for hormone tablets, with full-scale operations scheduled to begin in 2023. - FY2022-Q3Addition of the full-scale operations start dateAnnual report
「To meet increased demand for these key products, the company will build a new tablet production building at the Toyama Plant for manufacturing hormone tablets, with full-scale operations scheduled to begin in 2023. It will expand production capacity for hormone tablets and fulfill its responsibility to ensure a stable supply.」
States that, in response to increased demand for its major products, the company is constructing a new tablet manufacturing building for hormone tablets, scheduled to begin full-scale operations in 2023. - FY2021AdvancedAnnual report
「Toyama Plant Tablet production building (Building 6) 3,822 1,190 Internal funds, etc. December 2020 June 2022」
It discloses concrete progress on the plan to build Building 6, with a total planned investment of ¥3,822 million, ¥1,190 million already paid and completion scheduled for June 2022. - FY2021-Q3RestatedAnnual report
「In connection with planned capital investment at the Toyama Plant under the medium-term management plan from the current consolidated fiscal year onward, the company reviewed the actual use of its property, plant and equipment and reconsidered its depreciation method.」
It continues to explain the plan on the assumption of the capital investment at the Toyama Plant under the medium-term management plan, but does not provide the investment amount, completion date or any new progress update. - FY2021-Q1RestatedAnnual report
「In connection with planned capital investment at the Toyama Plant under the medium-term management plan from the current consolidated fiscal year onward, the company reviewed the actual use of its property, plant and equipment and reconsidered its depreciation method.」
It reiterates the planned capital investment at the Toyama Plant under the medium-term management plan, but does not provide a new investment amount, deadline or progress update. - FY2020First statedAnnual report
「Toyama Plant Tablet production building (Building 6) ¥3,800 million ¥204 million Internal funds, etc. December 2020 June 2022」
It describes the plan to build Building 6 at the Toyama Plant, with a total planned investment of ¥3,800 million, ¥204 million already paid, construction commencing in December 2020 and completion scheduled for June 2022.